ResMed Reports Strong Q2 2026 Earnings with Double-Digit Growth and FDA Clearance
RMD sits 29% above its 52-week low of $199.92.
Summary
ResMed Inc. announced robust second-quarter fiscal year 2026 results, featuring 11% revenue growth, 15% diluted EPS increase, and expanded gross margins, alongside an FDA clearance for an AI-enabled medical device and a quarterly cash dividend.
Key Events · Earnings and Guidance · RMD
-
Strong Q2 Financial Performance
Revenue grew 11% to $1.4 billion, with diluted EPS increasing 15% to $2.68, reflecting robust demand and operational efficiency.
-
Gross Margin Expansion
Non-GAAP gross margin improved by 310 basis points to 62.3%, driven by manufacturing efficiencies and component cost improvements.
-
FDA Clearance for AI Device
Received FDA clearance for 'Smart Comfort,' an AI-enabled digital medical device designed to personalize CPAP comfort settings and improve patient adherence.
-
Share Repurchase Program
Repurchased 704,000 shares for $175 million during the quarter, demonstrating active capital management.
Analysis · RMD · Industrial Applications And Services
ResMed's latest 8-K filing highlights a strong operational quarter, demonstrating solid execution and growth across its core businesses. The double-digit increases in revenue and earnings per share, coupled with significant gross margin expansion, indicate healthy demand for its sleep and respiratory care devices and the effectiveness of its digital health ecosystem. The FDA clearance for the AI-enabled 'Smart Comfort' device is a notable product development that could enhance patient adherence and market positioning. Furthermore, the company's share repurchase program underscores its commitment to returning capital to shareholders. These results suggest continued positive momentum and reinforce the company's leadership in its sector.
At the time of this filing, RMD was trading at $257.61 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $37.6B. The 52-week trading range was $199.92 to $293.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.